1 day ago · Merck’s (NYSE: MRK) Q4 and full-year 2024 results reflect strong growth. Our company announced Q4 worldwide sales of $15.6 billion, an increase of 7% from Q4 2023. …

1 day ago · Fourth-Quarter Worldwide Sales Were $15.6 Billion, an Increase of 7% From Fourth Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 9% Fourth-Quarter …

1 day ago · Merck anticipates full-year 2025 sales to be between $64.1 billion and $65.6 billion, including a negative impact of foreign exchange of approximately 2% at mid-January 2025 …

6 hours ago · Total Revenue: $15.6 billion, an increase of 7% (9% excluding foreign exchange impact). Human Health Sales Growth: 8%, driven primarily by oncology. Animal Health Sales …

17 hours ago · Merck (NYSE: MRK) Q4 2024 Earnings Call Feb 04, 2025, 9:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants. Prepared Remarks: …

1 day ago · Merck (MRK-9.81%) Q4 2024 Earnings Call Feb 04, 2025, 9:00 a.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. …

1 day ago · Excluding items, Merck & Co Inc. reported adjusted earnings of $4.372 billion or $1.72 per share for the period. Analysts projected $1.67 per share Revenue: $15.624 billion in Q4 …

1 day ago · Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.

20 hours ago · Merck MRK-9.07%decrease; red down pointing triangle shares tumbled more than 11% Tuesday morning after the drugmaker gave 2025 revenue guidance that fell short of …

1 day ago · Global pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6.8% year on year to $15.62 billion. …